Alberta Investment Management Corp Invests $5.06 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Alberta Investment Management Corp bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 7,100 shares of the biopharmaceutical company’s stock, valued at approximately $5,058,000.

Other large investors also recently made changes to their positions in the company. Mizuho Securities USA LLC increased its stake in shares of Regeneron Pharmaceuticals by 625.5% during the third quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company’s stock worth $62,382,000 after purchasing an additional 51,162 shares during the period. Principal Financial Group Inc. grew its position in Regeneron Pharmaceuticals by 1.7% during the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock worth $181,961,000 after buying an additional 2,828 shares in the last quarter. Simplify Asset Management Inc. grew its position in Regeneron Pharmaceuticals by 50.8% during the third quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company’s stock worth $10,082,000 after buying an additional 3,231 shares in the last quarter. Golden State Equity Partners grew its position in Regeneron Pharmaceuticals by 1,479.1% during the fourth quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company’s stock worth $967,000 after buying an additional 1,272 shares in the last quarter. Finally, Catalytic Wealth RIA LLC acquired a new stake in Regeneron Pharmaceuticals during the third quarter worth approximately $1,334,000. Institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on REGN. Piper Sandler reduced their price target on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a research report on Monday, January 27th. UBS Group downgraded Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $1,130.00 to $738.00 in a research report on Thursday, January 16th. Morgan Stanley reduced their price target on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. BMO Capital Markets reduced their target price on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a report on Tuesday, February 4th. Finally, Truist Financial reduced their target price on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $685.66 on Thursday. The stock has a 50-day moving average price of $700.92 and a 200-day moving average price of $887.66. Regeneron Pharmaceuticals, Inc. has a 1-year low of $642.00 and a 1-year high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The firm has a market cap of $74.96 billion, a PE ratio of 17.91, a price-to-earnings-growth ratio of 2.26 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period last year, the business posted $11.86 EPS. As a group, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be paid a $0.88 dividend. The ex-dividend date is Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.51%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.